New radioimmunotherapy approach shows potential to cure HER2-positive breast cancer
A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 (HER2)-positive breast cancer, according to new research published in the November issue of The Journal of Nuclear Medicine. The regimen, which pre-treats the tumor before delivering targeted alpha-radioimmunotherapy, resulted in durable major responses–including histologic cures–with minimal toxicities, paving the way for a safer and…